Molbio Diagnostics
OPENIPO Date: 10 Aug - 12 Aug 2026
Listing Date: 17 Aug 2026
Price Range
₹768 to ₹807
Issue Size
940 Cr
Min Investment
₹13,824
Lot Size
18 Shares
Schedule of Molbio Diagnostics
Issue open date
10 Aug 2026
Issue close date
12 Aug 2026
UPI mandate deadline
12 Aug 2026 (5 PM)
Allotment finalization
13 Aug 2026
Share credit
14 Aug 2026
Listing date
17 Aug 2026
Mandate end date
27 Aug 2026
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 940 Cr |
| Fresh Issue | 0.25 Cr |
| Offer for Sale | 0.92 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 13 Aug 2026 |
| Allotment Link | {Link} |
Grey Market PremiumNew
Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | Ipo Price | GMP | Estimated Listing Price |
|---|---|---|---|
| 10 Aug 2026 | ₹807 | ₹135 | ₹942 (16.73%) |
| 9 Aug 2026 | ₹807 | ₹132 | ₹939 (16.36%) |
| 8 Aug 2026 | ₹807 | ₹130 | ₹937 (16.11%) |
| 7 Aug 2026 | ₹807 | ₹180 | ₹987 (22.3%) |
| 6 Aug 2026 | ₹807 | ₹220 | ₹1027 (27.26%) |
| 5 Aug 2026 | ₹807 | ₹170 | ₹977 (21.07%) |
| 4 Aug 2026 | ₹807 | ₹0 | ₹807 (0%) |
Performance Molbio Diagnostics
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| ₹768 to ₹807 | .... | .... | .... |
About Molbio Diagnostics
Molbio Diagnostics is a healthcare diagnostics company focused on developing and manufacturing point-of-care diagnostic technologies. Its flagship Truenat platform is a portable, battery-operated real-time PCR system designed to provide rapid molecular testing, particularly in resource-limited settings. The company generates revenue through the sale of Truenat devices and recurring sales of disease-specific micro-PCR test kits. Its test menu covers diseases such as tuberculosis, COVID-19, Hepatitis B & C, HIV and HPV, while its subsidiaries also operate in radiology and digital pathology.
| Founded in | 2010 |
| Managing director | Satyajeet Mehta |
| Parent organization | Molbio Diagnostics Limited |
Financial Overview
Strengths
- Proprietary Truenat molecular diagnostic platform provides a differentiated point-of-care testing solution.
- Portable and battery-operated systems are well suited for rural, remote and resource-limited healthcare settings.
- Recurring revenue potential from the sale of Truenat-compatible test kits after device installation.
- Broadening test menu covering major infectious diseases such as TB, HIV, Hepatitis and HPV.
- Growing international presence and adoption of Truenat can support global expansion and scalability.
Risks
- Dependence on the Truenat platform means technological, regulatory or commercial issues could materially affect the business.
- Diagnostics is a highly regulated industry, requiring continuous compliance with quality and regulatory standards across different countries.
- Competition from established global molecular diagnostics companies and alternative testing technologies may pressure growth and pricing.
- Demand can be influenced by government healthcare programs, public procurement and infectious-disease testing volumes.
- Expansion into new markets requires significant investment in regulatory approvals, distribution networks, manufacturing capacity and customer adoption.
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 1 |
| Non-Institutional Investors (NIIs) | 0.73 |
| Retail Individual Investors (RIIs) | 0.77 |
| Employee | 2.12 |
| Total | 0.83 |